Japan’s MHLW Reviews GSK’s Momelotinib for Myelofibrosis Treatment
The Ministry of Health, Labour and Welfare (MHLW) in Japan has accepted for review a...
AstraZeneca and Daiichi Sankyo Report Positive Results for Datopotamab Deruxtecan Combo in NSCLC
UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced positive data from a Phase Ib...
Sichuan Kelun Pharmaceutical Secures Exclusive Rights to TBM-001 for Bone Metastasis Diagnosis
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech...
Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...
Chongqing Lummy Pharmaceutical’s Subsidiary Receives NMPA Approval for CUD002 mRNA Vaccine
Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006), through its subsidiary Sichuan Cunde Therapeutics Co., Ltd,...
Dialaibo Biotechnology Secures Series A Funding to Boost R&D and Manufacturing
China-based Dialaibo (Zhangjiagang) Biotechnology Co., Ltd has reportedly raised close to RMB 100 million (USD...
Jiangsu Aidea Pharmaceutical Partners with National Medical Center for Infectious Disease on HIV Drug Development
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...
Dizal Pharmaceutical’s Golidocitinib NDA Accepted for Review by NMPA
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that the National Medical Products Administration...
Genesis MedTech Receives Chinese Market Approval for Antibacterial Absorbable Sutures
Singapore-based medical device company Genesis MedTech has announced that it has received market approval in...
Grand Pharmaceutical’s GSP301 NS Meets Primary Endpoint in Phase III SAR Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Phase III study (GSP...
Canton Biologics Secures Over RMB 300 Million in Series C Financing for Expansion
Canton Biologics Co., Ltd, a Guangzhou-based Contract Development and Manufacturing Organization (CDMO) specializing in biologic...
Menarini Group Secures Exclusive License for Astellas’ Smyraf in Taiwan
A. Menarini Asia-Pacific Holdings Pte. Ltd, a subsidiary of the Italy-based Menarini Group, has entered...
Haisco Pharmaceutical’s HSK16149 for Post-Herpes Neuralgia Accepted for NMPA Review
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the National Medical Products...
Asieris Pharmaceuticals’ APL-1202 Shows Positive Interim Analysis in MIBC Trial with BeiGene’s Tislelizumab
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has revealed positive results from a Phase...
AstraZeneca’s Fasenra Shows Non-Inferior Efficacy to Nucala in EGPA: Phase III Results
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has unveiled the results of a Phase III...
InnoCare Pharma and ArriVent Biopharma Partner on Clinical Study for Advanced NSCLC Treatment
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced that it has received the green...
EMA Approves Astellas’ Xtandi for Non-Metastatic Hormone-Sensitive Prostate Cancer
The European Medicines Agency (EMA) has granted Japan-based Astellas (TYO: 4503) an indication extension approval...
FDA Accepts Takeda’s Filing for Subcutaneous Entyvio as Maintenance Therapy for Crohn’s Disease
The US Food and Drug Administration (FDA) has accepted a filing from Japan-based Takeda (TYO:...
AbbVie’s Skyrizi Outperforms Janssen’s Stelara in Phase III Crohn’s Disease Trial
AbbVie (NYSE: ABBV) has announced early data from a Phase III trial that compared the...
Boehringer Ingelheim Gets NMPA Approval for Brigimadlin Safety and Efficacy Study in China
Germany-based Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical...